acridines has been researched along with Ovarian Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, N; Yang, L; Zuo, H | 1 |
| Bray, SE; Chakravarty, P; Ferguson, MJ; Gannon, AL; Sawers, L; Scott, AL; Smith, G; Vaidyanathan, A | 1 |
| Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH | 1 |
| Caponigro, F; de Balincourt, C; Dieras, V; Dittrich, C; Fumoleau, P; Kerbrat, P; Lacombe, D; Paoletti, X; Punt, C; Sorio, R | 1 |
| Alvarez, RD; Barnes, MN; Cohn, D; Estes, JM; Leath, CA; Modiano, MR; Sawyer, M; Straughn, JM; Williams, S | 1 |
| Bowling, MK; Chen, TL; Donehower, RC; Grochow, LB; Kaufmann, SH; Lubejko, BG; Noe, DA; Rowinsky, EK; Sartorious, SE | 1 |
| Helm, CW; Miller, DM; Shingleton, HM; Shrestha, K; Thomas, S | 1 |
| Balasubramaniam, S; Baron, AT; Boardman, CH; Lafky, JM; Maihle, NJ; Podratz, KC; Suman, VJ | 1 |
| Charlton, PA; Cree, IA; Neale, MH | 1 |
| Gowan, SH; Harrison, RJ; Kelland, LR; Neidle, S; Read, M; Reszka, AP; Romagnoli, B; Tanious, FA; Wilson, WD | 1 |
| Blessing, JA; Bookman, MA; Creasman, WT; Plaxe, SC | 1 |
| Blessing, JA; Carlson, J; Morgan, MA; Plaxe, SC | 1 |
| Dobryszycka, W; Narczeuska, B; Warwas, M | 1 |
| Dobryszycka, W; Gerber, J; Jablonski, K; Osada, J | 2 |
| Bec, I; Dobryszycka, W; Gerber, J; Jabloński, K | 1 |
| Gruca, S; Krzyzowska-Gruca, S; Kwaśniewska-Rokicińska, C; Vorbrodt, A | 1 |
| Dobryszycka, W; Gerber, J; Jabloński, K; Woźniak, M | 1 |
| Swiecki, J | 1 |
5 trial(s) available for acridines and Ovarian Neoplasms
| Article | Year |
|---|---|
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome | 2003 |
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Pyrazoles | 2006 |
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; Central Nervous System; Colorectal Neoplasms; DNA, Neoplasm; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intercalating Agents; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Pyrazoles; Remission Induction; Uterine Cervical Neoplasms | 1995 |
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Pyrazoles | 2002 |
Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
Topics: Acridines; Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles | 2002 |
15 other study(ies) available for acridines and Ovarian Neoplasms
| Article | Year |
|---|---|
Arborinine suppresses ovarian cancer development through inhibition of LSD1.
Topics: Acridines; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; China; Cisplatin; Epithelial-Mesenchymal Transition; Female; Histone Demethylases; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Ovary; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrahydroisoquinolines; Verapamil | 2016 |
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro.
Topics: Acridines; Antineoplastic Agents; Base Sequence; Deoxyribonuclease I; DNA, Neoplasm; Female; Genes, myc; HeLa Cells; Humans; Molecular Sequence Data; Oligonucleotides; Ovarian Neoplasms; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1993 |
Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Topics: Acridines; Adult; Aged; Biomarkers, Tumor; Carcinoma; Case-Control Studies; Chemotherapy, Adjuvant; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunosorbent Techniques; Laparotomy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Proto-Oncogene Mas; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured | 1999 |
Ex vivo activity of XR5000 against solid tumors.
Topics: Acridines; Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Humans; Luminescent Measurements; Male; Melanoma; Middle Aged; Ovarian Neoplasms; Skin Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors.
Topics: Acridines; Cell Division; Computer Simulation; Cytotoxins; DNA; Drug Design; Enzyme Inhibitors; Female; G-Quadruplexes; Humans; Inhibitory Concentration 50; Kinetics; Models, Molecular; Molecular Conformation; Ovarian Neoplasms; Solutions; Substrate Specificity; Surface Plasmon Resonance; Telomerase; Thermodynamics; Tumor Cells, Cultured | 2001 |
Blood serum peptidases in patients with ovarian carcinoma treated with Ledakrin.
Topics: Acridines; Amidohydrolases; Ascites; Cobalt; Female; gamma-Glutamyltransferase; Humans; Kidney; Leucyl Aminopeptidase; Liver; Nitracrine; Ovarian Neoplasms | 1977 |
Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. I. Behavior of serum protein fractions.
Topics: Acridines; Adenocarcinoma; Alpha-Globulins; Ascites; Blood Proteins; Cystadenocarcinoma; Electrophoresis, Paper; Female; gamma-Globulins; Humans; Ovarian Neoplasms; Remission, Spontaneous; Serum Albumin | 1971 |
Biochemical blood studies in patients with ovarian carcinoma treated with C-283. 3. Immunoelectrophoresis of serum proteins.
Topics: Acridines; Alpha-Globulins; Antineoplastic Agents; Ascites; Blood Proteins; Female; Haptoglobins; Humans; Immunoelectrophoresis; Immunoglobulin A; Immunoglobulin G; Immunoglobulins; Methylamines; Nitro Compounds; Ovarian Neoplasms; Propylamines; Serum Albumin; Transferrin | 1972 |
The influence of aminoacridine derivative (C-283) on the ultrastructural pattern of human carcinoma cells.
Topics: Acridines; Cell Nucleolus; Cell Nucleus; Depression, Chemical; Endoplasmic Reticulum; Female; Humans; Injections, Intraperitoneal; Microscopy, Electron; Ovarian Neoplasms; Peritoneum; Pleural Effusion; Propylamines; RNA | 1974 |
Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid.
Topics: Acridines; Adenocarcinoma; Adenocarcinoma, Papillary; Antineoplastic Agents; Ascites; Ascitic Fluid; Carcinoma; Cystadenocarcinoma; Cystadenoma; Dimethylamines; Dysgerminoma; Female; Haptoglobins; Humans; Injections, Intraperitoneal; Injections, Intravenous; Neuraminic Acids; Nitro Compounds; Ovarian Neoplasms; Remission, Spontaneous; Teratoma | 1973 |
Studies of cancer patients treated with acridine derivative (C-283). V. Lactate dehydrogenase of serum, leukocytes and erythrocytes.
Topics: Acridines; Blood Protein Electrophoresis; Erythrocytes; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Isoenzymes; L-Lactate Dehydrogenase; Leukocytes; Ovarian Neoplasms | 1974 |
[C-283 in the treatment of pleural and peritoneal effusions in cases of ovarian cancer].
Topics: Acridines; Ascites; Evaluation Studies as Topic; Female; Humans; Nitro Compounds; Ovarian Neoplasms; Pleural Effusion; Propylamines; Remission, Spontaneous | 1971 |
[C-283 in treatment of peritoneal and pleural effusions in patients with ovarian carcinoma].
Topics: Acridines; Aged; Antineoplastic Agents; Drug Tolerance; Female; Hemoperitoneum; Humans; Middle Aged; Ovarian Neoplasms; Pleural Effusion; Propylamines; RNA | 1971 |